Abstract
Objective to assess the variations of the blood levels of immunoglobulins (Ig) in septic shock patients treated with an Ig preparation enriched in IgM and IgA (eIg).
Design The blood levels of Ig in survivors (S) and non-survivors (NS) of a group of septic shock patients were measured before the initial administration (D0) and one (D1), four (D4) and seven (D7) days thereafter. The SAPS II score, the capillary permeability, the primary site of infection, the antibiotic appropriateness, the microorganisms isolated and the outcome at 28 days were also assessed.
Results In the interval D0-D7 the IgM increased significantly only in the S while remained stable in NS; the IgA significantly increased in both groups; the IgG did not vary significantly in both groups. At D7 the capillary permeability significantly decreased in S but not in NS.
Conclusions The kinetics of the different classes of Ig after eIg were different between S and NS. This could be related either to (a) different capillary permeability in the two groups and/or (b) higher Ig consumption in NS. Further studies to confirm the benefits of eIg in the treatment of sepsis syndrome, to define the specific target population and the correct eIg dose are warranted.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local Ethical Committe was informed of the study and authorized the data gathering because (a) the eIg preparation is routinely used as part of the standard of care of patients with septic shock; (b) the patients were not randomized; and (c) at the time of hospital or ICU admission the patients or their next of kin, subscribed a form allowing the use of their personal date (i.e. blood chemistries, cultures etc) for research purposes provided that they remain anonymous. 2.2.2016, 36.reg deg, Ethical Committee of the Azienda Sanitaria Universitaria di Trieste
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding No source of funding for the research reported has to be declared.
Conflict of Interest The authors declare that they have no conflict of interest.
Data Availability
all relevant data are available for the rewievers
